Loading
RANBP2 (E3 SUMO-protein ligase RanBP2) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.
E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Binds single-stranded RNA (in vitro).
Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.85, affected pathway 0.76, genetic association 0.10, somatic mutation 0.94). IntOGen calls it a driver in 7 cohorts (1 activating, 5 loss-of-function), covering Renal Clear Cell Carcinoma, Hepatocellular Carcinoma, Lung Squamous Cell Carcinoma, Neuroblastoma, Paraganglioma.
In plain words · RANBP2 (E3 SUMO-protein ligase RanBP2) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.
RANBP2 (E3 SUMO-protein ligase RanBP2) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.
E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates.
No product in this corpus aims at RANBP2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
First described 1995. Earliest sequence paper UniProt cites for the protein: Wu et al, J. Biol. Chem, 1995, "Nup358, a cytoplasmically exposed nucleoporin with peptide repeats, Ran-GTP binding sites, zinc fingers, a cyclophilin A homologous domain, and a leucine-rich region". Source.
Sources: HGNC HGNC:9848 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49792 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000153201 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: melanoma 0.52, skin cancer 0.55, breast cancer 0.52, lung cancer 0.59 (GraphQL API, CC0)); IntOGen RANBP2 (driver in 7 cohorts (Act 1, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Binds single-stranded RNA (in vitro). May bind DNA. Component of the nuclear export pathway. Specific docking site for the nuclear export factor exportin-1. Location: Nucleus; Nucleus membrane; Nucleus, nuclear pore complex; Nucleus envelope (UniProt). Locus 2q13 (HGNC).
Query for this target: (TITLE:"RANBP2" OR ABSTRACT:"RANBP2" OR TITLE:"RAN binding protein 2" OR ABSTRACT:"RAN binding protein 2" OR TITLE:"E3 SUMO-protein ligase RanBP2" OR ABSTRACT:"E3 SUMO-protein ligase RanBP2" OR TITLE:"NUP358" OR ABSTRACT:"NUP358" OR TITLE:"ADANE" OR ABSTRACT:"ADANE" OR TITLE:"ANE1" OR ABSTRACT:"ANE1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RANBP2, not a curated reading list.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Breast cancer (all types).
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen.